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REVIEWS
Non-specific effects of MMR vaccines on infectious disease related hospitalizations
during the second year of life in high-income countries: a systematic review and
meta-analysis
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ABSTRACT
Children who had received MMR as the most recent vaccine had a pooled 35% (95%CI: 12–53%) lower
risk for hospitalization due to any infectious disease, compared to children who had received DTaP as
the most recent vaccine (three studies, 1,919,192 children). The effect was stronger for respiratory tract
infections than for gastrointestinal infections. Two studies investigated MMR alone, compared to
concurrent administration of MMR and DTaP vaccines. Here, the pooled estimate for reduction in risk
of hospitalization for any infectious disease was smaller and not significant (15%; 95%CI: −9% to 34%).
Risk of bias was serious to critical in all studies. Moreover, two of the five studies demonstrated
a significantly reduced risk for a control outcome (hospitalization for injuries), strongly indicating healthy
vaccinee bias or residual confounding. The available evidence is insufficient to support a change in
current vaccination schedules.
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Introduction
Non-specific effects of vaccines are vaccine effects that are not
mediated by the effect of the vaccine on the targeted patho-
gen. Such non-specific effects of vaccines on child mortality
have first been reported from developing countries.1
Meanwhile, the non-specific vaccine effects have also been
reported for morbidity. While non-specific effects of live
vaccines appear to reduce mortality and morbidity, the oppo-
site was found for inactivated vaccines.2 Strong effects were
mainly observed in non-randomized studies. Attempts for
confirmation in randomized trials, however, often yielded
much smaller and mostly insignificant effects.3
More recently this work has been extended to industria-
lized countries.4 To measure the effect of live-attenuated
vaccines on infectious diseases not targeted by the vaccine
the studies investigated hospitalizations due to any infectious
disease in infants who received Measles, Mumps and Rubella
vaccine (MMR) after having received a Diphtheria, Tetanus
and acellular Pertussis vaccine (DTaP), as compared to infants
who received the DTaP vaccine after the MMR vaccine or
never received MMR after the DTaP (see Figure 1 describing
the principle of these studies). A protective effect of MMR
vaccine as compared to DTaP containing vaccines as the most
recent vaccine on the risk of hospitalizations for infectious
diseases in the second year of life was reported.4
Exposure to MMR and DTaP containing vaccines as last
vaccine in the second year of life is potentially modifiable by
adaptation of vaccine recommendations. Such modification
might have a substantial effect on the burden of infectious
diseases in infants in the second year of life in industrialized
countries. We, therefore, attempted to summarize and evalu-
ate the evidence of the effect of MMR as the last vaccine on
hospitalization for infectious disease in the second year of life.
Methods
This review was conducted according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement.5 The review protocol was registered in the
International prospective register of systematic reviews
(PROSPERO) under the registration number CRD42018100666.
Eligibility criteria
To be eligible, a study had to meet the following PICO
(population, intervention, comparator, outcome) criteria:
● P: Children from 12 to 24 months of age, excluding
children with any chronic disease, as main population,
who could receive further vaccination in the second year
of life in accordance with the national vaccination
recommendations.
● I: Receipt of MMR comprising vaccine as the most
recent vaccine.
● C: Receipt of a DTaP comprising vaccine as the most
recent vaccine.
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● O: As the main outcome hospitalization for any infec-
tious disease was chosen. For subgroup analysis, upper
and lower respiratory tract infections as well as gastro-
intestinal infections were chosen.
This review considered non-randomized studies as well as
randomized controlled trials. Only studies from high-income
countries were included (see Appendix for definition of high-
income countries). Only articles published in the English
language were included.
Search strategy
A systematic computerized literature search of three electro-
nic databases including PubMed, EMBASE and Medline was
conducted on May 21st 2018 via the Ovid search interface,
which provides access to studies published from 1974
onwards. The search strategy combined keywords as shown
in the appendix. No filters were applied.
Study selection
EndNote software X7 was used to export identified references.
All duplicates were removed. Two researchers (AXS and RvK)
completed all stages of the screening process independently
and discrepancies were resolved by discussion.
The search term was confined to MMR vaccines. One
study,6 however, included varicella vaccination, another
live vaccine, in the analysis, assuming similar effects for
MMR and the varicella vaccine. Because it was impossible
to disentangle the effects and because the number of
children receiving varicella alone was small (of the live
vaccines, 88% received MMR containing vaccines by the
age of 16 months),6 we included this study in the analysis.
Also in one study7 MMR was given with Meningococcal
C (MenC), an inactivated vaccine.
For sake of simplicity, we refer to MMR vaccines compared to
DTaP containing vaccines throughout the paper, acknowledging
the limitation that in one study a small proportion of the pre-
sumed MMR effect may be caused by varicella vaccination only
and the possible interference of MenC vaccination in another
study.
Data extraction and quality assessment
The data were collected into an adapted excel workbook based on
the template for data extraction developed by the Editorial
Resources Committee of the Cochrane Collaboration.8 Two
reviewers independently extracted data on study characteristics,
participant description, intervention characteristics, and out-
comes. Differences were resolved by discussion. For included
studies, the ROBINS-I tool for assessing risk of bias in non-
randomized studies of interventions was used.9 Any discrepancies
were resolved by discussion, if necessary with further reviewers.
Data synthesis
The Hazard Ratios and 95% confidence intervals were synthe-
sized in a random-effects model using Review Manager 5.3.10
Also, heterogeneity and test for overall effect were assessed
using the software.
Quality of the body of evidence
The quality of the body of evidence was evaluated using the
Grading of Recommendations, Assessment, Development and
Evaluation (GRADE)11 system. Publication Bias could not be
assessed due to the low number of included studies.
Results
Study selection
The database literature search resulted in 574 articles. After
removal of duplicates, the titles and abstracts of 452 studies
were screened. Four hundred and nineteen studies were
excluded because they did not address the topic of interest
or were not conducted in the target setting (high-income
country). The full texts of 33 papers were further assessed
for eligibility. Of these, 12 were excluded because they did not
address hospitalization for infectious disease. Two studies
were from low-income countries. Three studies had
a different intervention than the interventions determined in
the protocol. And eleven studies were reviews or comments.
Finally, five studies were included in the qualitative and
quantitative analysis (see Figure 2 for a PRISMA flowchart).
Figure 1. Schematic depiction of the study designs considered for this review.
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Study characteristics
The shared exposures analyzed in all studies are depicted in
Figure 1. In essence, all studies compare the risk of hospita-
lization for children because of an infection, by having MMR
or DTaP as the most recent vaccine when admitted to hospi-
tal. The main characteristics of the included studies are sum-
marized in Table 1. One Danish study examined only MMR
as the most recent vaccine for intervention with 510,935
included children.4 The Dutch study examined MMR com-
bined with Men-C as the most recent vaccine with 1,096,594
included children.7 One study examining concurrent admin-
istration of MMR and DTaP-IPV-Hib vaccines consisted of
520,859 children.12 The study from the USA investigating
both concurrent administration and live vaccine alone as the
most recent vaccine included 311,663 children.6 The study
addressing RSV hospitalization had MMR alone for interven-
tion, it included 168,511 children.13
The Danish studies4,12,13 investigating MMR compared to
children with DTaP containing vaccine as last vaccine
required at least two doses of DTaP containing vaccines as
a prerequisite to be included in the study. In the Dutch study,7
the requirement was four doses DTaP, while it was three
doses in the US study.6 In the three studies with no over-
lapping populations4,6,7 MMR containing vaccines as most
recent vaccination was assessed as the intervention.
In two study populations, concurrent administration as the
most recent vaccine was also reported in the same paper
(Bardenheier et al. 2017) or in a separate paper (Sorup et al. 2016).
The main outcome for all studies was hospitalization for an
infectious disease. All papers also performed subgroup analy-
sis by stratifying the outcome by upper and lower respiratory
tract infection and gastrointestinal tract infections. RSV as an
outcome of special interest was addressed in a subpopulation
of the Danish study population (Sorup et al. 2015).
The Danish studies4,12,13 defined exposure as MMR exclu-
sively. In the Dutch7 study, MMR was administered with
MenC on the same day and thus concurrently. In both the
Dutch7 and Danish4,12,13 studies DTaP was given as
a combination vaccine with HiB. Pneumococcal conjugate
vaccination was given on the same day in the Dutch study.7
The US study6 defined live vaccines as MMR, Varicella or
MMRV. In this study, inactivated vaccines included
diphtheria-tetanus-acellular pertussis, inactivated polio virus,
Haemophilus influenzae type b, pneumococcal conjugate
Figure 2. Flowchart of the selection process in accordance with the PRISMA statement adapted by Moher et al.
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vaccine, hepatitis B vaccine, and hepatitis A vaccine (and
combined vaccines with these antigens).
Risk of bias within studies
Results of risk of bias assessment are summarized in Table 2.
For two studies4,7 the overall risk of bias was classified as
critical because of a significant association to the control
outcome in the same direction (reduced risk for injuries
with MMR as last vaccine). For the other three studies6,12,13
risk of bias was classified as serious because structural
inequality between intervention and control group could not
be ruled out. Design factors seem plausible which influence
the time point of the intervention and therefore the group
status of a child as well as the observed outcome. Children
inherently more prone to infectious disease could have
a delayed MMR vaccination and therefore a longer control
group status (DTaP as most recent vaccine), while having
more hospital admissions for infectious disease accounting
for residual confounding.
Additionally, in the Bardenheier et al. study6 the number of
confounders considered for adjustment was lower than in the
Danish and Dutch studies: no adjustments for household
income, parental education or migration background were
made in this study. We did not take account of this limitation
to change the risk of bias from serious to critical because the
overall impact of including covariates in all studies was only
of small size.
Results of individual studies
As shown in Table 3, the main finding of the Sorup 2014 study4
was a small but significant reduction in the overall risk for
hospitalizations after MMR as last vaccine. This was mainly
driven by the association between MMR as last vaccine and
lower respiratory tract infections. The 95% confidence intervals
for upper and lower respiratory tract infections overlapped
widely, whereas the respective 95% confidence intervals for
gastrointestinal infections were shifted toward unity. The con-
trol outcome suggested a small but significant effect on emer-
gency department visits following unintentional injury.
The Sorup 2015 study13 was based on a sub-sample of the
study population analyzed in the 2014 study4 for which infor-
mation on RSV was available. The impact on RSV was similar
Table 1. Characteristics of the studies included in the systematic review.
Authors,
Year
Study
Design Setting
Study
period Population Data origins Sponsoring
Conflict
of
interest Vaccines Outcomes
Sorup, S.,
et al.,
(2014)4
Cohort
study
Denmark 1997–
2008
510,935
children
11–24
months
Danish National Patient
Register; Danish Civil
Registration System; Danish
Medical Birth Register; Data
was linked with personal
identification number
Health Foundation;
Rosalie Petersen
Foundation; Novo
Nordisk Foundation
None MMR
DTaP-IPV-Hib
Hospital
admission
for any
infectious
disease
Sorup, S.,
et al.,
(2015)13
Cohort
study
Denmark 1997–2004 168,511
children
14–23
months
Danish National Patient
Register; Danish Civil
Registration System; Danish
Medical Birth Register; Data
was linked with personal
identification number
Health Foundation;
Rosalie Petersen
Foundation; Novo
Nordisk Foundation;
Danish National Research
Foundation
None MMR
DTaP-IPV-Hib
Respiratory
syncytial
virus
hospital
contact
Sorup, S.,
et al.,
(2016)11
Cohort
study
Denmark 1997–
2009
520,859
Children
15–24
months
Danish National Patient
Register; Danish Civil
Registration System; Danish
Medical Birth Register; Data
was linked with personal
identification number
Danish Council for
Independent
Research; Health
Foundation; Rosalie
Petersens Foundation,
Novo Nordisk
Foundation; European
Research Council; Danish
National Research
Foundation
None MMR
DTaP-IPV-Hib
Concurrent
administration of
these two
Hospital
admission
for any
infectious
disease
Tielemans,
S. et al.,
(2017)10
Cohort
study
Netherlands 2005–
2012
1,096,594
Children
11–24
months
Electronic national
immunization register;
national medical register;
population register; Data
was linked with a unique
personal identifier
Dutch Ministry of Health None MMR +
meningococcal C
DTaP-IPV-Hib
+pneumococcal
Vaccination
Hospital
admission
for any
infectious
disease
Bardenheier,
B. H.,
et al.,
(2017)12
Cohort
study
USA 2005–
2014
311,663
children
16–24
months
MarketScan Commercial
Claims Databases which
provides data from
commercial health
insurance claims
US Department of
Health and Human
Services
None Inactivated
vaccines:
DTaP, IPV, Hib,
pneumococcal
conjugate
vaccine, hepatitis
B vaccine, and
hepatitis
A vaccine
Live vaccines:
MMR, Varicella
Hospital
admission
for any
infectious
disease
MMR – Measles, Mumps and Rubella vaccine; DTaP – Diphtheria, Tetanus, and acellular Pertussis vaccine; IPV – inactivated Polio virus; Hib – Haemophilus influenzae
type B vaccine
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Table 2. Risk of bias summary applying ROBINS-I.
ROBINS-I risk of bias Sorup et al., 2014 Sorup et al., 2015 Sorup et al., 2016 Tielemanns et al., 2017 Bardenheier et al., 2017
Bias due to confounding Critical Serious Serious Critical Serious
Bias in selection of participants into the study Low Low Low Low Low
Bias in classification of interventions Moderate Moderate Moderate Moderate Moderate
Bias due to deviations from intended interventions Low Low Low Low Low
Bias due to missing data Low Low Low Low Low
Bias in measurement of outcome Moderate Moderate Moderate Moderate Moderate
Bias in selection of the reported result Low Low Low Low Low
Overall risk of Bias Critical Serious Serious Critical Serious
Table 3. Findings of the studies included in the systematic review.
Authors,
Year
Absolute hospital
admissions per Person-
Years Adjusted parameters
Adjusted relative effects
(95% CI)
Negative control outcomes
(95% CI)
Sorup, S.,
et al.,
(2014)4
Hospital admission for
any infectious disease:
DTaP-IPV-Hib3 as
most recent vaccine:
20 743/167693
MMR as most recent
vaccine:
21 311/239 642
Hospital admission for
upper respiratory tract
infections:
DTaP-IPV-Hib3 as
most recent vaccine:
8 516/167 693
MMR as most recent
vaccine:
8 599/239 642
Hospital admission for
lower respiratory tract
infections:
DTaP-IPV-Hib3 as
most recent vaccine:
7 223/167 693
MMR as most recent
vaccine:
6 941/239 642
Hospital admission for
gastrointestinal tract
infections:
DTaP-IPV-Hib3 as
most recent vaccine:
2 881/167 693
MMR as most recent
vaccine:
3 206/239 642
Sex, maternal smoking during pregnancy, birth weight,
gestational age, cesarean delivery, chronic diseases, number of
admissions for infections before age 11 months, admitted to
hospital for any cause within the last 30 days, maternal age at
birth of the child, highest educational level for the female adult
in the household, parental place of birth, adult composition of
the household, income quintiles for the household, other children
in the household, and population density
Hospital admission for
any infectious disease:
MMR as most recent
vaccine vs. DTaP-IPV-
Hib3:
IRR 0.86 (0.84–0.88)
Hospital admission for
upper respiratory tract
infections:
MMR as most recent
vaccine vs. DTaP-IPV-
Hib3:
IRR: 0.86 (0.82–0.89)
Hospital admission for
lower respiratory tract
infections:
MMR as most recent
vaccine vs. DTaP-IPV-
Hib3:
IRR: 0.80 (0.76–0.84)
Hospital admission for
gastrointestinal tract
infections:
MMR as most recent
vaccine vs. DTaP-IPV-
Hib3:
IRR: 0.93 (0.87–1.00)
Emergency department visits
following unintentional injury
MMR as most recent vaccine
vs. DTaP-IPV-Hib3:
Unadjusted:
IRR 0.96 (0.94–0.98)
Adjusted:
IRR 0.97 (0.95–0.99)
Sorup, S.,
et al.,
(2015)13
Respiratory syncytial
virus hospital contact:
DTaP-IPV-Hib3 as
most recent vaccine:
320/35 995
MMR as most recent
vaccine:
568/92 593
Sex, birth weight, gestational age, cesarean section,
chronicdiseases, number of admissions between 1 month of age
and date of DTaP-IPV-Hib3 vaccination, admission from date of
DTaP-IPV-Hib3 vaccination until 14 months of age,maternal age
at birth of the child, parental place of birth, adult composition of
the household, and other children in the household
Respiratory syncytial
virus hospital contact:
MMR as most recent
vaccine vs. DTaP-IPV-
Hib3:
IRR: 0.78 (0.66–0.93)
Emergency room visits due to
accidents
MMR as most recent vaccine
vs. DTaP-IPV-Hib3:
IRR: 1.02 (0.98–1.06)
Sorup, S.,
et al.,
(2016)11
Hospital admission for
any infectious disease:
Concurrent
administration:
332/2 971
MMR as most recent
vaccine:
24 027/267 582
Date of birth, mother smoking during pregnancy, sex, birth
weight, gestational age, cesarean section, chronic diseases,
number of infectious disease admissions before 15 months of
age, admitted to hospital for any cause within the last 30 days,
maternal age at birth of the child, highest educational level for
the female adult in the household, parental place of birth, adults
in the household, income quintiles for the household, other
children in the household, and population density
Hospital admission for
any infectious disease:
Simultaneous MMR and
DTaP-IPV-Hib vs. MMR:
IRR: 1.04 (0.94–1.17)
Emergency room visits
due to accidents
Simultaneous MMR and
DTaP-IPV-Hib vs. MMR:
Unadjusted:
IRR: 1.08 (1.03–1.13)
Adjusted:
IRR: 1.00 (0.95–1.04)
(Continued )
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Table 3. (Continued).
Authors,
Year
Absolute hospital
admissions per Person-
Years Adjusted parameters
Adjusted relative effects
(95% CI)
Negative control outcomes
(95% CI)
Tielemans,
S. et al.,
(2017)10
Hospital admission for
any infectious disease:
DTaP-IPV-Hib+PCV as
most recent vaccine:
4 111/284 786
MMR+MenC as most
recent vaccine:
6 850/776 456
Hospital admission for
upper respiratory tract
infections:
DTaP-IPV-Hib+PCV as
most recent vaccine:
1 664/285 664
MMR+MenC as most
recent vaccine:
2 765 / 782 900
Hospital admission for
lower respiratory tract
infections:
DTaP-IPV-Hib+PCV as
most recent vaccine:
1 234/285 731
MMR+MenC as most
recent vaccine:
2 120/783 457
Hospital admission for
gastrointestinal tract
infections:
DTaP-IPV-Hib+PCV as
most recent vaccine:
1 816 /285 657
MMR+MenC as most
recent vaccine:
2 942/782 668
Sex, chronic disease, admission for any reason at age 8 months,
birth weight, gestational age, maternal age and parity, parental
country of birth, and postcode
Hospital admission for
any infectious disease:
MMR+MenC as most
recent vaccine: HR: 0.62
(0.57 to 0.67)
Hospital admission for
upper respiratory tract
infections:
MMR+MenC as most
recent vaccine:
HR: 0.54 (0.48 to 0.62)
Hospital admission for
lower respiratory tract
infections:
MMR+MenC as most
recent vaccine:
HR: 0.56 (0.49 to 0.66)
Hospital admission for
gastrointestinal tract
infections:
HR: 0.70 (0.61 to 0.80)
Admitted to hospital for
more than one day because
of injury or poisoning
MMR+MenC as most recent
vaccine vs. DTaP-IPV-Hib
+PCV:
Unadjusted:
HR: 0.81 (0.71 to 0.93)
Adjusted:
HR: 0.84 (0.73 to 0.96)
Bardenheier,
B. H.,
et al.,
(2017)12
Hospital admission for
any infectious disease:
Live as most recent
vaccine:
241/16 002
Inactivated as most
recent vaccine:
1 807/137 156
Hospital admission for
upper respiratory tract
infections:
Live as most recent
vaccine:
103/16 093
Inactivated as most
recent vaccine:
665/137 650
Hospital admission for
lower respiratory tract
infections:
Live as most recent
vaccine:
108/16 086
Inactivated as most
recent vaccine:
958/137 519
Hospital admission for
gastrointestinal tract
infections:
Live as most recent
vaccine:
28/16 138
Inactivated as most
recent vaccine:
146/137 884
Chronic conditions, low birth weight, premature, number of
hospitalizations prior to age 16 months, number of outpatient
visits prior to age 16 months, region, urban/rural, and mother’s
age
Hospital admission for
any infectious disease:
Live as most recent
vaccine:
HR: 0.50 (0.43, 0.57)
Hospital admission for
upper respiratory tract
infections:
Live as most recent
vaccine:
HR: 0.41 (0.32, 0.51)
Hospital admission for
lower respiratory tract
infections:
Live as most recent
vaccine:
HR: 0.45 (0.36, 0.56)
Hospital admission for
gastrointestinal tract
infections:
HR: 0.92 (0.59, 1.42)
Emergency room visit for an
unintentional injury
Live vs. inactivated:
HR: 1.16 (0.90, 1.48)
MMR – Measles, Mumps and Rubella vaccine; DTaP – Diphtheria, Tetanus, and acellular Pertussis vaccine; IPV – inactivated Polio virus; Hib – Haemophilus influenzae
type B vaccine; PCV – Pneumococcal Conjugate Vaccine; HR – Hazard Ratio; IRR – Incidence Rate Ratio; CI – Confidence Interval.
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in size to that observed for lower respiratory infections in the
entire population.
The Dutch study7 suggested a substantially higher impact of
MMR on the rate of hospitalizations, as compared to those
observed in the studies4,12,13 fromDenmark. The control outcome
suggested a similar and significant effect on emergency depart-
ment visits following unintentional injury. As in the Sorup
studies4,12,13 the effect was stronger for upper and lower respira-
tory tract infections and not as strong for gastrointestinal
infections.
The US study6 reported an even more pronounced effect of
MMR on hospitalization. As in the Sorup4,12,13 and Dutch7
studies, the effect was stronger for lower and upper respira-
tory tract infections. There was no significant effect on hospi-
tal admissions for gastrointestinal infections. Interestingly, in
this study no effect on the control outcome “emergency room
visits for unintentional injury” was observed.
For two populations6,12 the potential effect of MMR on
hospitalization for infections was also addressed if MMR was
given with a DTaP containing vaccine compared to MMR
alone. The Danish paper12 did not find a significant relative
effect, whereas the US study6 observed a favorable effect of the
administration of MMR alone.
Synthesis of results
Figure 3 shows the result of the meta-analysis for hospital
admissions due to any infectious disease after receipt of MMR
as the most recent vaccine, as compared to receipt of DTaP as
the most recent one. The pooled overall effect suggested
a reduction of the relative risk by about one third with large
heterogeneity between the studies.
Figure 4 shows the result of the meta-analysis for hospita-
lization due to any infectious disease after receipt of MMR as
the most recent vaccine, as compared to concurrent
administration of a MMR and DTaP vaccine as the most
recent vaccination. Here, a smaller and non-significant reduc-
tion in risk was observed, while heterogeneity was high again.
GRADE evidence quality
GRADE evidence quality was very low for all outcomes. This
was mainly due to high risk of bias and substantial hetero-
geneity between studies (see Supplementary Table 6).
Discussion
The results of this systematic review show that five studies
performed in high-income countries reported a non-specific
protective effect of MMR as the most recent vaccine for
prevention of hospitalizations related to infectious diseases
in the second year of life compared to children with DTaP
containing vaccine as the most recent vaccine. The summary
effect estimate from three studies suggests a reduction by 35%.
High risk of bias in the individual studies and substantial
inconsistency between study results, however, preclude any
firm conclusions for potential modification of time schedules
in national immunization programs.
We used the ROBINS-I tool9 for assessment of risk of bias.
This recently developed tool applies the approach of compar-
ing a given non-randomized study to a hypothetical rando-
mized “target trial” to analyze potential sources of bias in the
former. Identification of and adjustment for potential con-
founders is one of the key domains of ROBINS-I, including
the issue of residual confounding. Residual confounding,
however, appears possible for the main Danish4 and Dutch7
studies because of significant effects on the control outcome
in the same direction. Robins-I explicitly recommends that
any association seen for a control outcome (or so-called
negative outcome) in the same direction as the main outcome
Figure 3. Hospital admissions for any infectious disease MMR vs. DTaP as most recent vaccine (confounder-adjusted estimates were used from the primary studies).
Figure 4. Hospital admissions for any infectious disease MMR vs. concurrent administration of MMR and DTaP (confounder-adjusted estimates were used from the
primary studies).
HUMAN VACCINES & IMMUNOTHERAPEUTICS 7
should be considered as indication of bias, irrespective of
difference in the strength of effect. In conclusion, all studies
were considered to be at serious to critical risk of bias. The
confidence regarding the overall effect estimate was further
reduced by substantial inconsistency between studies, because
of differences in concurrent administration of vaccines and
strength of the effect.
The authors of the Dutch study7 doubt the validity of their
findings themselves, because of a relatively strong and signifi-
cant effect on the control outcome. Additionally, comparing
infectious disease hospitalization rates after 4 versus 3 DTaP
vaccinations, they found a protective effect of the fourth
DTaP dose, similar in size to that of MMR. Consequently,
these authors concluded that the effects observed in studies on
this subject might not be specific for live vaccines, but may
indicate healthy vaccinee bias.
The US study6 reports the strongest effects. However,
adjustment for confounders was less complete than in the
other studies. Moreover, there was a discrepancy between
the reported rates for hospitalization for any infectious disease
after live vaccine and inactivated vaccine and the derived
adjusted relative risks for any infectious disease hospitaliza-
tion. The adjusted relative risk was almost halved whereas the
absolute risk for live vaccine was higher than after inactivated
vaccine. This discrepancy could not be resolved by correspon-
dence with the first author or the institution (neither
responded).
In the studies6,12 that compared the effect of MMR alone to
concurrent MMR and DTaP administration, the within study
effects appear to be lower after concurrent administration,
which might indicate effect modification by administration of
DTaP. However, pooling the estimates of the two studies led to
high heterogeneity and a non-significant pooled estimate.
Heterogeneity also pertains to the exposures compared. In
the Netherlands,7 MMR was consistently given concurrently
with MenC, an inactivated vaccine. In the US study,6 any live
vaccine (including MMRV or Varicella alone) was considered
and compared to DTaP or to a number of different potential
other inactivated vaccines.
Some consistency between the studies may indicate
a shared causal principal or shared confounding directed at
the prevention of respiratory infections: In all studies, the
effect was more pronounced against respiratory than gastro-
intestinal infections. The considerable effect size against RSV
reported in the Danish study13 published in 2015 points to
a potential clinical relevance of MMR as last vaccine since
RSV is a major cause of life-threatening acute respiratory
infections in children, globally.14
So far the data of the Danish group5 elaborating further on
indirect evidence against selection bias are unique. The emer-
gence of the MMR effect only 2 weeks after MMR vaccination
hints to plausibility: Immune modulation after MMR vaccina-
tion is unlikely to emerge immediately after vaccination,
whereas a healthy vaccinee effect related to the timing of
vaccination would be present immediately after vaccination.
Additionally, the similar findings regarding the reverse sche-
dule cannot be explained by vaccinating healthier children
with MMR earlier. Further study in populations where the
reverse schedule is more widely used is needed for confirma-
tion of these findings.
Strengths and Limitations
A limitation of this systematic review is the paucity and
heterogeneity of the published studies on this issue.
Additionally, the individual studies were of limited quality.
In the ROBINS-I9 tool studies are considered as critical for
the risk of bias, if the control outcome “strongly suggests
unmeasured confounding”. In fact, it is not entirely clear what
the authors of ROBINS-I mean by “strongly suggests unmea-
sured confounding”. If “strongly” is interpreted with regard to
effect size and confidence intervals, one has to admit that the
effect sizes of the negative control outcomes are smaller than
those of the target outcomes, while the confidence intervals of
the former are sometimes close to 1. However, “strongly” might
also be interpreted as “we have robust evidence for the presence
of residual confounding”. In this sense, analyses showed that in
the studies under discussion here, an effect on the negative
control outcomes was observed in the unadjusted data, but
also after adjustment for (known and observable) confounders.
We would like to interpret this as robust evidence for the
presence of residual confounding. Moreover, we do not know
to what extent the unmeasured confounding influences the
target outcome. Even a weak effect on the control outcome
could mean a strong effect on the target outcome, because of
unmeasured variables. It is uncertain if the control outcome and
the measured outcome are influenced equally.
Despite the limitations of the individual studies, we did
a meta-analysis to summarize the findings of the three relevant
studies since the effect was in a similar direction. The justifica-
tion for performing a meta-analysis on heterogeneous studies of
limited quality might be questioned. We presented the meta-
analysis nevertheless, to provide a summary, while acknowl-
edging the limitations of the summary estimate presented.
In conclusion, in non-randomized studies, having received
a live vaccine as the most recent vaccine is associated with
a decreased risk of hospitalization for any infectious disease
during the second year of life in high-income countries.
However, due to severe study limitations, the available evidence
is insufficient to support a change in current vaccination sche-
dules. In vaccination programs in populations with persistent
measles circulation and only one MMR dose in the first 2 years
postponing MMR to make it the most recent vaccination would
evidently put the most vulnerable by measles, infants and young
toddlers, at risk for acquiring measles. Because of the small but
relevant risk of primary MMR vaccine failures, this may also
apply to the second dose in countries where this is recom-
mended. For these populations, the risk of measles due to
postponement of the MMR dose, which depends on the size of
measles circulation in the population, must be balanced against
the potential benefit of a reduced risk for respiratory infections.
In a population with an ongoing 2 dose MMR vaccination in
the first 2 years of life and successful measles elimination, it
might be possible to randomize the timing of the second MMR
dose in order to obtain irrefutable evidence for a reduced risk for
respiratory infections related to MMR given as the last vaccine.
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